Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from NeOnc Technologies Holdings, Inc. ( (NTHI) ) is now available.
On September 10, 2025, NeOnc Technologies Holdings, Inc. announced that the FDA has authorized the company to proceed with Phase IIa/IIb of its NEO212-01 clinical trial. This authorization follows the successful completion of Phase I, where NEO212 demonstrated safety at specified doses. NEO212 is a first-in-class oral chemotherapy candidate combining Temozolomide with NeOnc’s proprietary NEO100, designed to overcome current treatment limitations for brain cancers. The Phase II trial will expand patient enrollment across leading U.S. cancer centers, positioning NEO212 as a potential new standard of care for brain cancer.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a multi-Phase II clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system cancers and other challenging malignancies. The company’s portfolio includes proprietary drugs like NEO100 and NEO212, aimed at delivering transformative outcomes for patients globally.
Average Trading Volume: 216,599
Technical Sentiment Signal: Strong Buy
Learn more about NTHI stock on TipRanks’ Stock Analysis page.
Trending Articles:
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects